
|Articles|November 26, 2012
FDA panel votes against OTC use of OAB agent
An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
US Disease Tracker Launches to Monitor Vaccine-Preventable Illnesses
2
FDA Approves Tivicay PD to Treat HIV Infection in Newborns
3
FDA Authorizes First Ketone, Blood Sugar Monitor for Diabetes
4
Diabetes Medications Adjustments for Older Adults Lower Than ADA Guidelines
5
























